Regorafenib to help prevent cancer return after treatment
Part of Bones, joints & muscles, Cancer clinical trials.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old when you sign consent.
- Your bone cancer is a high-grade bone sarcoma confirmed by biopsy (for example osteosarcoma or Ewing sarcoma).
- There is measurable remaining cancer that cannot be removed by surgery, either at diagnosis or after relapse.
- Your cancer is not getting worse at the start of the study, based on the study’s scan rules.
- You finished your last cancer treatment (chemo or surgery) at least 4 weeks ago, but no more than 2 months ago.
- Your blood counts and organ tests (liver, kidney, and pancreas) must be within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This early-phase study tests sulfatinib in children, teens, and young adults with high-grade osteosarcoma that has returned or does not respond to standard treatment. It may help shrink tumors or control the disease, and it also aims to find safe dosing.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
Hear when a new Bone Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.